Depomed (DEPO) Tops Q2 EPS by 3c, Updates Guidance
Tweet
Share
E-mail
Get Alerts DEPO Hot Sheet
Price: $7.30 --0%
Financial Fact:
Net income (loss): -12.89M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net income (loss): -12.89M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $63.3 million versus the consensus estimate of $63.8 million.
Guidance:
The Company is increasing its full-year adjusted EBITDA range to $145 million to $155 million from the previous range of $125 million to $135 million.
For earnings history and earnings-related data on Depomed (DEPO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
